Two studies presented at the American Academy of Neurology’s 66th Annual Meeting, 2014, may offer hope to people with migraines. The two phase II drugs (ALD403 and LY2951742) significantly reduced the number of migraine days per month. Read more.
© 2020 HealthCom Media
All rights reserved. No part of this website or publication may be reproduced, stored, or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright holder